United Therapeutics Other Current Assets

United Therapeutics's other current assets stands at $320M as of June 2026. That compares with $1.7B in the prior-year period — down 81.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

United Therapeutics reported $320M in other current assets versus $1.7B a year earlier — a 81.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1.7B in the prior-year period — down 81.2% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how United Therapeutics's other current assets evolved across reporting periods, while the comparison chart places UTHR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. United Therapeutics's reading of $320M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.